INCY (Incyte Genomics Inc)
Insider Trading Activity
Every open-market purchase and sale reported by INCY officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-27 | Ramitpal K Basi | EVP, Human Resources | F | — | — |
| 2026-08-20 | PABLO J CAGNONI | President, Global Head of R&D | Sell | — | — |
| 2026-08-14 | PABLO J CAGNONI | President, Global Head of R&D | Sell | — | — |
| 2026-08-07 | Patrick A Mayes | EVP & Chief Scientific Officer | MIXED | — | — |
| 2026-08-07 | PABLO J CAGNONI | President, Global Head of R&D | Sell | — | — |
| 2026-08-07 | Patrick A Mayes | EVP & Chief Scientific Officer | MIXED | — | — |
| 2026-08-07 | PABLO J CAGNONI | President, Global Head of R&D | Sell | — | — |
| 2026-08-04 | PABLO J CAGNONI | President, Global Head of R&D | Sell | — | — |
| 2026-08-04 | Patrick A Mayes | EVP & Chief Scientific Officer | MIXED | — | — |
| 2026-07-27 | Michael James Morrissey | EVP, Head of Tech. Operations | A | — | — |
| 2026-07-27 | Lee Heeson | EVP, Head of Incyte Intl | A | — | — |
| 2026-07-20 | Richard A. Hoffman | EVP & General Counsel | A | — | — |
| 2026-07-20 | PABLO J CAGNONI | President, Global Head of R&D | A | — | — |
| 2026-07-20 | Mohamed Khairie Issa | EVP, Head of U.S. Commercial | MIXED | — | — |
| 2026-07-20 | Ramitpal K Basi | EVP, Human Resources | A | — | — |
| 2026-07-20 | Patrick A Mayes | EVP & Chief Scientific Officer | A | — | — |
| 2026-07-20 | David H Gardner | EVP, Chief Strategy Officer | A | — | — |
| 2026-07-20 | William Meury | Chief Executive Officer | A | — | — |
| 2026-07-20 | Steven H Stein | CMO & Head of Late-Stage Dev. | MIXED | — | — |
| 2026-07-20 | Thomas Tray | Principal Accounting Officer | A | — | — |
| 2026-07-16 | PABLO J CAGNONI | President, Global Head of R&D | F | — | — |
| 2026-07-16 | Steven H Stein | CMO & Head of Late-Stage Dev. | MIXED | — | — |
| 2026-07-16 | Mohamed Khairie Issa | EVP, Head of U.S. Commercial | F | — | — |
| 2026-07-16 | Patrick A Mayes | EVP & Chief Scientific Officer | F | — | — |
| 2026-07-16 | Thomas Tray | Principal Accounting Officer | F | — | — |
| 2026-07-07 | Thomas Tray | Principal Accounting Officer | F | — | — |
| 2026-07-07 | Patrick A Mayes | EVP & Chief Scientific Officer | F | — | — |
| 2026-07-07 | Steven H Stein | CMO & Head of Late-Stage Dev. | F | — | — |
| 2026-07-07 | William Meury | Chief Executive Officer | F | — | — |
| 2026-07-02 | Paul J Clancy | Director | A | — | — |
| 2026-07-02 | EDMUND HARRIGAN | Director | A | — | — |
| 2026-07-02 | JULIAN BAKER | Director | A | — | — |
| 2026-06-10 | JACQUALYN A FOUSE | Director | A | — | — |
| 2026-06-10 | Katherine A High | Director | A | — | — |
| 2026-06-10 | OTIS W BRAWLEY | Director | A | — | — |
| 2026-06-10 | JEAN JACQUES BIENAIME | Director | A | — | — |
| 2026-06-10 | Paul J Clancy | Director | A | — | — |
| 2026-06-10 | EDMUND HARRIGAN | Director | A | — | — |
| 2026-06-10 | FELIX BAKER | Director | A | — | — |
| 2026-06-08 | Thomas Tray | Principal Accounting Officer | MIXED | — | — |
| 2026-06-03 | PABLO J CAGNONI | President, Global Head of R&D | F | — | — |
| 2026-05-28 | JEAN JACQUES BIENAIME | Director | MIXED | — | — |
| 2026-05-28 | Thomas Tray | Principal Accounting Officer | Sell | — | — |
| 2026-05-21 | Paul J Clancy | Director | MIXED | — | — |
| 2026-05-20 | PABLO J CAGNONI | President, Global Head of R&D | A | — | — |
| 2026-05-20 | Steven H Stein | CMO & Head of Late-Stage Dev. | A | — | — |
| 2026-05-11 | 667, L.P. | Director | M | — | — |
| 2026-05-06 | Suketu Upadhyay | EVP & Chief Financial Officer | A | — | — |
| 2026-04-21 | PABLO J CAGNONI | President, Global Head of R&D | MIXED | — | — |
| 2026-04-17 | Steven H Stein | CMO & Head of Late-Stage Dev. | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 28,482,491 | — |
| — | Director | 28,468,279 | — |
| — | Director | 12,213,272 | — |
| — | Director | 3,485,752 | — |
| — | Director | 3,115,871 | — |
| — | Director | 3,098,808 | — |
| — | Director | 651,082 | — |
| — | Special Advisor to the CEO | 352,703 | — |
| — | Director | 344,064 | — |
| — | Director | 314,600 | — |
| — | Director | 314,600 | — |
| — | Director | 284,025 | — |
| — | Director | 271,813 | — |
| — | Director | 261,911 | — |
| — | President, Global Head of R&D | 183,200 | — |
| — | Chief Executive Officer | 183,129 | — |
| — | Director | 181,362 | — |
| — | EVP & Chief Financial Officer | 114,652 | — |
| — | EVP, Human Resources | 106,482 | — |
| — | EVP, Head of Discovery Chem | 98,980 | — |
| — | Director | 92,290 | — |
| — | Director | 92,042 | — |
| — | EVP, Head of U.S. Commercial | 71,797 | — |
| — | EVP & General Counsel | 69,724 | — |
| — | Chief Drug Discovery Scientist | 66,504 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the INCY quote page; the site-wide leaderboard is on the insider transactions hub.